# Dinner, according to GLP1 Me

> GLP1 Me pulls up a chair for retatrutide research: hunger, smaller portions, the feeling of control and the less comfortable findings beside them.

**Appetite, in company**

The name ends with me. I want room at the table for hunger, fullness and the business of eating, alongside the weight curves.

## Eating in the exit interviews

I pulled up a chair for the retatrutide paper that involves a conversation. In [exit interviews with 40 phase 2 trial participants](https://pubmed.ncbi.nlm.nih.gov/41216380/), 31 of the 36 people who received retatrutide reported changes in eating behaviour within the first 8 weeks. Their accounts included less frequent hunger, greater satiety, smaller portions, changed food preferences and a stronger sense of control over eating.

Control deserves the closest attention here, I think. A portion has a size; the experience of deciding when to stop eating has a texture that a weight curve cannot supply. These interviews make that experience available for discussion. They also concern a particular group of trial participants, speaking about perceived benefits.

The breadth of these accounts impresses me. A single, ideal appetite sounds much less appealing. Hunger, fullness and control deserve separate seats at this table.

## Weight change in the phase 2 trial

The [48-week obesity trial](https://pubmed.ncbi.nlm.nih.gov/37366315/) enrolled 338 adults. At the study’s 12 mg dose, mean body-weight change was −24.2%, compared with −2.1% for placebo. That is a substantial result.

That percentage makes a tempting opening. Still, the interview accounts give the weight result an everyday setting: portions, preferences and the feeling of being able to stop. The measurements and the accounts answer different questions. The accounts bring daily life into the argument; the group result still matters at its proper scale.

![Two horizontal bars compare mean body-weight change for retatrutide and placebo.](images/weight-at-48-weeks.svg)

*Mean body-weight change at 48 weeks in the [phase 2 obesity trial](https://pubmed.ncbi.nlm.nih.gov/37366315/); retatrutide was studied at 12 mg in the group shown.*

## Appetite and discomfort

The same [phase 2 report recorded dose-related gastrointestinal adverse events](https://pubmed.ncbi.nlm.nih.gov/37366315/), mostly mild to moderate, and a dose-dependent rise in heart rate. Those findings have a place beside the pleasant accounts of smaller portions.

A smaller meal can earn enthusiasm too easily, to my mind. The appeal of feeling more in control of food says little about the acceptability of feeling unwell. The [tolerability essay](/tolerability) stays with the less comfortable findings, while [hunger and fullness](/appetite) returns to what people actually reported.

## Retatrutide

The name GLP-1 Me is wider than the subject of these essays. This table is currently set around retatrutide, described in a [clinical profile as an investigational GIP, GLP-1 and glucagon receptor agonist](https://pubmed.ncbi.nlm.nih.gov/39724554/). Its appetite story comes with additional receptor biology; the [three-receptor essay](/three-receptors) gets into the especially awkward animal experiment.

And after the treatment period? [Appetite after the trial](/after-treatment) is where curiosity turns into impatience for me: I want the conversation about eating to continue beyond the period of weight loss.

---

GLP-1 Me is my table for published research on appetite, not a business or a source of medical advice.